{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:28:11Z","timestamp":1793838491941,"version":"4.6.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2026JJ80994"],"award-info":[{"award-number":["2026JJ80994"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Teaching Reform Research Project of Central South University","award":["2025jy22"],"award-info":[{"award-number":["2025jy22"]}],"id":[{"id":"https:\/\/ror.org\/00f1zfq44","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Hunan Provincial Key Laboratory of the Traditional Chinese Medicine Agricultural Biogenomic"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10637-026-01627-x","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:43:05Z","timestamp":1781664185000},"page":"345-353","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical features, diagnosis and prognosis of nivolumab-associated fulminant type 1 diabetes"],"prefix":"10.1007","volume":"44","author":[{"given":"Qiong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoquan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"1627_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252\u2013264. https:\/\/doi.org\/10.1038\/nrc3239","journal-title":"Nat Rev Cancer"},{"key":"1627_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1080\/14712598.2020.1749593","volume":"20","author":"L Chiew Woon","year":"2020","unstructured":"Chiew Woon L, Joycelyn Jie Xin L, Su Pin C (2020) Nivolumab for the treatment of hepatocellular carcinoma. Expert Opin Biol Ther 20:687\u2013693. https:\/\/doi.org\/10.1080\/14712598.2020.1749593","journal-title":"Expert Opin Biol Ther"},{"key":"1627_CR3","doi-asserted-by":"publisher","first-page":"3926","DOI":"10.1200\/JCO.24.01125","volume":"42","author":"GV Long","year":"2024","unstructured":"Long GV, Lipson EJ, Hodi FS et al (2024) First-line nivolumab plus relatlimab versus nivolumab plus ipilimumab in advanced melanoma: an indirect treatment comparison using RELATIVITY-047 and CheckMate 067 trial data. J Clin Oncol 42:3926\u20133934. https:\/\/doi.org\/10.1200\/JCO.24.01125","journal-title":"J Clin Oncol"},{"key":"1627_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114296","volume":"211","author":"M Reck","year":"2024","unstructured":"Reck M, Ciuleanu TE, Schenker M et al (2024) Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial. Eur J Cancer 211:114296. https:\/\/doi.org\/10.1016\/j.ejca.2024.114296","journal-title":"Eur J Cancer"},{"key":"1627_CR5","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158\u2013168. https:\/\/doi.org\/10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"1627_CR6","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/jdi.12024","volume":"3","author":"A Imagawa","year":"2012","unstructured":"Imagawa A, Hanafusa T, Awata T et al (2012) Report of the committee of the Japan diabetes society on the research of fulminant and acute-onset type 1 diabetes mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus (2012). J Diabetes Investig 3:536\u2013539. https:\/\/doi.org\/10.1111\/jdi.12024","journal-title":"J Diabetes Investig"},{"key":"1627_CR7","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.2337\/dc25-0579","volume":"48","author":"S Noso","year":"2025","unstructured":"Noso S, Chujo D, Imagawa A et al (2025) Rapid and slow progressors toward \u03b2-cell depletion and their predictors in type 1 diabetes: prospective longitudinal study in Japanese Type 1 Diabetes (TIDE-J). Diabetes Care 48:1438\u20131445. https:\/\/doi.org\/10.2337\/dc25-0579","journal-title":"Diabetes Care"},{"key":"1627_CR8","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/jdi.14362","volume":"16","author":"F Kamitani","year":"2025","unstructured":"Kamitani F, Nishioka Y, Koizumi M et al (2025) Immune checkpoint inhibitor-related type 1 diabetes incidence, risk, and survival association. J Diabetes Investig 16:334\u2013342. https:\/\/doi.org\/10.1111\/jdi.14362","journal-title":"J Diabetes Investig"},{"key":"1627_CR9","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s13340-018-0362-2","volume":"10","author":"MY Baden","year":"2018","unstructured":"Baden MY, Imagawa A, Abiru N et al (2018) Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy. Diabetol Int 10:58\u201366. https:\/\/doi.org\/10.1007\/s13340-018-0362-2","journal-title":"Diabetol Int"},{"key":"1627_CR10","doi-asserted-by":"publisher","first-page":"e1473","DOI":"10.1210\/clinem\/dgad329","volume":"108","author":"A Imagawa","year":"2023","unstructured":"Imagawa A, Hanafusa T (2023) Fulminant type 1 diabetes-east and west. J Clin Endocrinol Metab 108:e1473\u2013e1478. https:\/\/doi.org\/10.1210\/clinem\/dgad329","journal-title":"J Clin Endocrinol Metab"},{"key":"1627_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3749","volume":"40","author":"I Hormaz\u00e1bal-Aguayo","year":"2024","unstructured":"Hormaz\u00e1bal-Aguayo I, Ezzatvar Y, Huerta-Uribe N, Ram\u00edrez-V\u00e9lez R, Izquierdo M, Garc\u00eda-Hermoso A (2024) Incidence of type 1 diabetes mellitus in children and adolescents under 20 years of age across 55 countries from 2000 to 2022: A systematic review with meta-analysis. Diabetes Metab Res Rev 40:e3749. https:\/\/doi.org\/10.1002\/dmrr.3749","journal-title":"Diabetes Metab Res Rev"},{"key":"1627_CR12","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1080\/14740338.2024.2446422","volume":"25","author":"K Meng","year":"2026","unstructured":"Meng K, Fu S, Huang Y, Chen W, Zou W (2026) Fulminant type 1 diabetes mellitus: a neglected but high-risk adverse event associated with immune checkpoint inhibitors. Expert Opin Drug Saf 25:507\u2013514. https:\/\/doi.org\/10.1080\/14740338.2024.2446422","journal-title":"Expert Opin Drug Saf"},{"key":"1627_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.968798","volume":"13","author":"J Qiu","year":"2022","unstructured":"Qiu J, Luo S, Yin W, Guo K, Xiang Y, Li X, Liu Z, Zhou Z (2022) Characterization of immune checkpoint inhibitor-associated fulminant type 1 diabetes associated with autoantibody status and ethnic origin. Front Immunol 13:968798. https:\/\/doi.org\/10.3389\/fimmu.2022.968798","journal-title":"Front Immunol"},{"key":"1627_CR14","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/jdi.13143","volume":"11","author":"M Miyauchi","year":"2020","unstructured":"Miyauchi M, Toyoda M, Zhang J et al (2020) Nivolumab-induced fulminant type 1 diabetes with precipitous fall in C-peptide level. J Diabetes Investig 11:748\u2013749. https:\/\/doi.org\/10.1111\/jdi.13143","journal-title":"J Diabetes Investig"},{"key":"1627_CR15","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.2337\/diacare.26.8.2345","volume":"26","author":"A Imagawa","year":"2003","unstructured":"Imagawa A, Hanafusa T, Uchigata Y et al (2003) Fulminant type 1 diabetes: a nationwide survey in Japan. Diabetes Care 26:2345\u20132352. https:\/\/doi.org\/10.2337\/diacare.26.8.2345","journal-title":"Diabetes Care"},{"key":"1627_CR16","doi-asserted-by":"publisher","first-page":"861","DOI":"10.2337\/dc06-2281","volume":"30","author":"A Hekkala","year":"2007","unstructured":"Hekkala A, Knip M, Veijola R (2007) Ketoacidosis at diagnosis of type 1 diabetes in children in northern Finland: temporal changes over 20 years. Diabetes Care 30:861\u2013866. https:\/\/doi.org\/10.2337\/dc06-2281","journal-title":"Diabetes Care"},{"key":"1627_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3317","volume":"36","author":"S Luo","year":"2020","unstructured":"Luo S, Ma X, Li X, Xie Z, Zhou Z (2020) Fulminant type 1 diabetes: a comprehensive review of an autoimmune condition. Diabetes Metab Res Rev 36:e3317. https:\/\/doi.org\/10.1002\/dmrr.3317","journal-title":"Diabetes Metab Res Rev"},{"key":"1627_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00592-011-0362-1","volume":"50","author":"S Luo","year":"2013","unstructured":"Luo S, Zhang Z, Li X et al (2013) Fulminant type 1 diabetes: a collaborative clinical cases investigation in China. Acta Diabetol 50:53\u201359. https:\/\/doi.org\/10.1007\/s00592-011-0362-1","journal-title":"Acta Diabetol"},{"key":"1627_CR19","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1210\/jc.2018-00728","volume":"103","author":"K Clotman","year":"2018","unstructured":"Clotman K, Janssens K, Specenier P, Weets I, De Block CEM (2018) Programmed cell death-1 inhibitor-induced type 1 diabetes mellitus. J Clin Endocrinol Metab 103:3144\u20133154. https:\/\/doi.org\/10.1210\/jc.2018-00728","journal-title":"J Clin Endocrinol Metab"},{"key":"1627_CR20","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1530\/EJE-19-0291","volume":"181","author":"JMK de Filette","year":"2019","unstructured":"de Filette JMK, Pen JJ, Decoster L, Vissers T, Bravenboer B, Van der Auwera BJ (2019) Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review. Eur J Endocrinol 181:363\u2013374. https:\/\/doi.org\/10.1530\/EJE-19-0291","journal-title":"Eur J Endocrinol"},{"key":"1627_CR21","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1007\/s00262-017-2033-8","volume":"66","author":"ML Gauci","year":"2017","unstructured":"Gauci ML, Laly P, Vidal-Trecan T et al (2017) Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review. Cancer Immunol Immunother 66:1399\u20131410. https:\/\/doi.org\/10.1007\/s00262-017-2033-8","journal-title":"Cancer Immunol Immunother"},{"key":"1627_CR22","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/dmrr.2779","volume":"32","author":"G Huang","year":"2016","unstructured":"Huang G, Yin M, Xiang Y et al (2016) Persistence of glutamic acid decarboxylase antibody (GADA) is associated with clinical characteristics of latent autoimmune diabetes in adults: a prospective study with 3-year follow-up. Diabetes Metab Res Rev 32:615\u2013622. https:\/\/doi.org\/10.1002\/dmrr.2779","journal-title":"Diabetes Metab Res Rev"},{"key":"1627_CR23","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1007\/s00125-009-1539-9","volume":"52","author":"Y Kawabata","year":"2009","unstructured":"Kawabata Y, Ikegami H, Awata T et al (2009) Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset. Diabetologia 52:2513\u20132521. https:\/\/doi.org\/10.1007\/s00125-009-1539-9","journal-title":"Diabetologia"},{"key":"1627_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3731","volume":"40","author":"J Qiu","year":"2024","unstructured":"Qiu J, Yin W, Wang R, Luo S, Zhou Z (2024) Fulminant type 1 diabetes: focusing ontriggering factors. Diabetes Metab Res 40:e3731. https:\/\/doi.org\/10.1002\/dmrr.3731","journal-title":"Diabetes Metab Res"},{"key":"1627_CR25","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1084\/jem.20022125","volume":"198","author":"MJ Ansari","year":"2003","unstructured":"Ansari MJ, Salama AD, Chitnis T et al (2003) The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 198:63\u201369. https:\/\/doi.org\/10.1084\/jem.20022125","journal-title":"J Exp Med"},{"key":"1627_CR26","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1007\/s12272-010-1115-3","volume":"33","author":"TJ Won","year":"2010","unstructured":"Won TJ, Jung YJ, Kwon SJ et al (2010) Forced expression of programmed death-1 gene on T cell decreased the incidence of type 1 diabetes. Arch Pharm Res 33:1825\u20131833. https:\/\/doi.org\/10.1007\/s12272-010-1115-3","journal-title":"Arch Pharm Res"},{"key":"1627_CR27","doi-asserted-by":"publisher","first-page":"22584","DOI":"10.3390\/ijms160922584","volume":"16","author":"V Perri","year":"2015","unstructured":"Perri V, Russo B, Crin\u00f2 A et al (2015) Expression of PD-1 molecule on regulatory T lymphocytes in patients with insulin-dependent diabetes mellitus. Int J Mol Sci 16:22584\u201322605. https:\/\/doi.org\/10.3390\/ijms160922584","journal-title":"Int J Mol Sci"},{"key":"1627_CR28","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/cei.12603","volume":"180","author":"R Fujisawa","year":"2015","unstructured":"Fujisawa R, Haseda F, Tsutsumi C et al (2015) Low programmed cell death-1 (PD-1) expression in peripheral CD4(+) T cells in Japanese patients with autoimmune type 1 diabetes. Clin Exp Immunol 180:452\u2013457. https:\/\/doi.org\/10.1111\/cei.12603","journal-title":"Clin Exp Immunol"},{"key":"1627_CR29","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.diabres.2017.07.036","volume":"133","author":"T Iijima","year":"2017","unstructured":"Iijima T, Kato K, Jojima T, Tomotsune T, Fukushima M, Suzuki K, Aso Y (2017) Circulating CD4+PD-1+ and CD8+PD-1+ T cells are profoundly decreased at the onset of fulminant type 1 diabetes and are restored by treatment, contrasting with CD4+CD25+FoxP3+ regulatory T cells. Diabetes Res Clin Pract 133:10\u201312. https:\/\/doi.org\/10.1016\/j.diabres.2017.07.036","journal-title":"Diabetes Res Clin Pract"},{"key":"1627_CR30","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.2337\/dc18-2518","volume":"42","author":"S Yoneda","year":"2019","unstructured":"Yoneda S, Imagawa A, Hosokawa Y et al (2019) T-lymphocyte infiltration to islets in the pancreas of a patient who developed type 1 diabetes after administration of immune checkpoint inhibitors. Diabetes Care 42:e116\u2013e118. https:\/\/doi.org\/10.2337\/dc18-2518","journal-title":"Diabetes Care"},{"key":"1627_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","volume":"9","author":"JR Brahmer","year":"2021","unstructured":"Brahmer JR, Abu-Sbeih H, Ascierto PA et al (2021) Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer 9:e002435. https:\/\/doi.org\/10.1136\/jitc-2021-002435","journal-title":"J Immunother Cancer"},{"key":"1627_CR32","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L et al (2022) Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 33:1217\u20131238. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.001","journal-title":"Ann Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01627-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-026-01627-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01627-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:04:43Z","timestamp":1793837083000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-026-01627-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1627"],"URL":"https:\/\/doi.org\/10.1007\/s10637-026-01627-x","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"20 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Statement of Ethics is not applicable because this study is based exclusively on published literature.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}